1. Yoon HI, Kwon OR, Kang KN, et al. Diagnostic Value of Combining Tumor and Inflammatory Markers in Lung Cancer. J Cancer Prev. 2016;21(3):187-193. doi: 10.15430/JCP.2016.21.3.187.
2. Chalela R, Bellosillo B, Curull V, et al. EGFR and KRAS Mutations in the Non-Tumoral Lung. Prognosis in Patients with Adenocarcinoma. J Clin Med. 2019;8(4):529. doi: 10.3390/jcm8040529.
3. Dhont L, Pintilie M, Kaufman E, et al. Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC). BMC cancer 2018, 18(1):429. doi: 10.1186/s12885-018-4215-y.
4. Zhang W, Li J, Li R, et al. Efficacy and safety of iodine-125 radioactive seeds brachytherapy for advanced non-small cell lung cancer-A meta-analysis. Brachytherapy 2018, 17(2):439-448.doi: 10.1016/j.brachy.2017.11.015.
5. Chiu CH, Chou TY, Chiang CL, et al. Should EGFR mutations be tested in advanced lung squamous cell carcinomas to guide frontline treatment? Cancer chemotherapy and pharmacology. 2014;74(4):661-665.doi: 10.1007/s00280-014-2536-3.
6. Park JY, Jang SH, Kim HI, et al. Thyroid transcription factor-1 as a prognostic indicator for stage IV lung adenocarcinoma with and without EGFR-sensitizing mutations. BMC cancer 2019, 19(1):574.doi: 10.1186/s12885-019-5792-0.
7. Deng C , Zhang Y , Ma Z, et al. Prognostic value of epidermal growth factor receptor gene mutation in resected lung adenocarcinoma. J Thorac Cardiovasc Surg. 2020;S0022-5223(20)31529-4. doi: 10.1016/j.jtcvs.2020.05.099.
8. Hidayat M, Mitsuishi Y, Takahashi F, et al. Role of FBXW7 in the quiescence of gefitinib-resistant lung cancer stem cells in EGFR-mutant non-small cell lung cancer. Bosn J Basic Med Sci. 2019;19(4):355-367. doi: 10.17305/bjbms.2019.4227.
9. Huang X, Xia L, Lan F, et al. Treatment of Nivolumab Results in Hyperprogressive Disease in a Patient Harboring EGFR Exon 20 Insertion and MYC Amplification. Journal of thoracic oncologyJ Thorac Oncol. 2019;14(9):e189-e191. doi: 10.1016/j.jtho.2019.04.009.
10. Boulkroun S, Fay M, Zennaro MC, et al. Characterization of rat NDRG2 (N-Myc downstream regulated gene 2), a novel early mineralocorticoid-specific induced gene.J Biol Chem. 2002;277(35):31506-31515. doi: 10.1074/jbc.M200272200.
11. Guo Y, Li X, Sun X, et al. Combined Aberrant Expression of NDRG2 and LDHA Predicts Hepatocellular Carcinoma Prognosis and Mediates the Anti-tumor Effect of Gemcitabine. Int J Biol Sci. 2019;15(9):1771-1786. doi: 10.7150/ijbs.35094. eCollection 2019.
12. Li SJ, Wang WY, Li B, et al. Expression of NDRG2 in human lung cancer and its correlation with prognosis. Med Oncol. 2013;30(1):421. doi: 10.1007/s12032-012-0421-7.
13. Wang XF, Wu YH, Wang MS, et al. CEA, AFP, CA125, CA153 and CA199 in malignant pleural effusions predict the cause. Asian Pac J Cancer Prev. 2014;15(1):363-8. doi: 10.7314/apjcp.2014.15.1.363.
14. Jiang ZF, Wang M, Xu JL. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer. Life Sci. 2018;194:1-6. doi: 10.1016/j.lfs.2017.12.020.
15. Vervoorts J, Luscher-Firzlaff J, Luscher B. The ins and outs of MYC regulation by posttranslational mechanisms. J Biol Chem. 2006;281(46):34725-34729. doi: 10.1074/jbc.R600017200.
16. Liu J, Levens D. Making myc. Curr Top Microbiol Immunol. 2006;302:1-32. doi: 10.1007/3-540-32952-8_1.
17. Yang YQ, Tian T, Zhu HY, et al. NDRG2 mRNA levels and miR-28-5p and miR-650 activity in chronic lymphocytic leukemia. BMC Cancer. 2018;18(1):1009. doi: 10.1186/s12885-018-4915-3.
18. Wang H, Wang W, Wang X, et al. Reduced N-Myc downstream-regulated gene 2 expression is associated with CD24 upregulation and poor prognosis in patients with lung adenocarcinoma. Med Oncol. 2012;29(5):3162-3168. doi: 10.1007/s12032-012-0231-y.
19. Cheng L, Alexander RE, MacIennan GT, et al. Molecular pathology of lung cancer: key to personalized medicine. Mod Pathol. 2012;25(3):347-69. doi: 10.1038/modpathol.2011.215.
20. Maemondo M, Inoue A, Kobayashi K, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med. 2010;362(25):2380-2388. doi: 10.1056/NEJMoa0909530.
21. Tran VT, Phan TT, Nguyen ST, et al. Smoking habit and chemo-radiotherapy and/or surgery affect the sensitivity of EGFR plasma test in non-small cell lung cancer. BMC Res Notes. 2020;13(1):367.doi: 10.1186/s13104-020-05209-9.
22. Sun Y, Wu M, Zhou M et al. Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: a retrospective multi-institutional analysis. BMC Cancer. 2020,20(1):646. doi: 10.1186/s12885-020-07122-7.
23. Catherine L , Michael C , Grzegorz JK. et al. Prognostic and predictive effects of TP53 co-mutation in patients with EGFR-mutated non-small cell lung cancer (NSCLC). Lung Cancer . 2017;111:23-29. DOI: 10.1016/j.lungcan.2017.06.014
24. Wang F , Zhao N, Gao G. et al. Prognostic value of TP53 co-mutation status combined with EGFR mutation in patients with lung adenocarcinoma. J Cancer Res Clin Oncol. 2020 Aug 2. doi: 10.1007/s00432-020-03340-5.
25. Yamashita T, Higashi M, Momose S, et al. Decreased MYC-associated factor X (MAX) expression is a new potential biomarker for adverse prognosis in anaplastic large cell lymphoma. Sci Rep. 2020;10(1):10391. doi: 10.1038/s41598-020-67500-w.
26. Kwak Y, Yun S, Nam SK, et al. Comparative analysis of the EGFR, HER2, c-MYC, and MET variations in colorectal cancer determined by three different measures: gene copy number gain, amplification status and the 2013 ASCO/CAP guideline criterion for HER2 testing of breast cancer. J Transl Med. 2017;15(1):167. doi: 10.1186/s12967-017-1265-x.
27. Li WY, Zhao TT, Xu HM, et al. The role of EGFR mutation as a prognostic factor in survival after diagnosis of brain metastasis in non-small cell lung cancer: a systematic review and meta-analysis. BMC cancer 2019, 19(1):145.doi: 10.1186/s12885-019-5331-z.